Prot#GS-US-419-3895: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

Project: Research project

Project Details

StatusActive
Effective start/end date7/19/177/19/22

Funding

  • Gilead Sciences, Inc. (Prot#GS-US-419-3895)